Correspondence 0001193125-26-242232 from Xilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc.
Date: May 27, 2026 · CIK: 0001840233 · Accession: 0001193125-26-242232
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295785
Letter
Re:Xilio Therapeutics, Inc. Registration Statement on Form S-3 Filed May 12, 2026
May 27, 2026
VIA EDGAR SUBMISSION
U.S. Securities and Exchange Commission
Division of Corporation Finance, Office of Life Sciences
100 F Street, NE
Washington, DC 20549
Attention: Lauren Hamill
File No. 333-295785 Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Xilio Therapeutics, Inc. hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-295785), so that it may become effective at 4:00 p.m., Eastern Time, on May 29, 2026, or as soon as practicable thereafter.
Very truly yours,
XILIO THERAPEUTICS, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP May 27, 2026 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Lauren Hamill Re:Xilio Therapeutics, Inc. Registration Statement on Form S-3 Filed May 12, 2026 File No. 333-295785 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Xilio Therapeutics, Inc. hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-295785), so that it may become effective at 4:00 p.m., Eastern Time, on May 29, 2026, or as soon as practicable thereafter. Very truly yours, XILIO THERAPEUTICS, Inc. By: /s/ René Russo Name: René Russo Title: President and Chief Executive Officer